
Oryzon Genomics SA
MAD:ORY

Intrinsic Value
The intrinsic value of one
ORY
stock under the Base Case scenario is
1.17
EUR.
Compared to the current market price of 2.71 EUR,
Oryzon Genomics SA
is
Overvalued by 57%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Oryzon Genomics SA
Fundamental Analysis


Revenue & Expenses Breakdown
Oryzon Genomics SA
Balance Sheet Decomposition
Oryzon Genomics SA
Current Assets | 5.4m |
Cash & Short-Term Investments | 3.8m |
Receivables | 1.6m |
Other Current Assets | 13.6k |
Non-Current Assets | 101.9m |
Long-Term Investments | 125.5k |
PP&E | 341.4k |
Intangibles | 99m |
Other Non-Current Assets | 2.4m |
Free Cash Flow Analysis
Oryzon Genomics SA
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Oryzon Genomics SA
Revenue
|
0
EUR
|
Cost of Revenue
|
-1.3m
EUR
|
Gross Profit
|
-1.3m
EUR
|
Operating Expenses
|
-3.6m
EUR
|
Operating Income
|
-4.9m
EUR
|
Other Expenses
|
652k
EUR
|
Net Income
|
-4.2m
EUR
|
ORY Profitability Score
Profitability Due Diligence
Oryzon Genomics SA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Score
Oryzon Genomics SA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
ORY Solvency Score
Solvency Due Diligence
Oryzon Genomics SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Score
Oryzon Genomics SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ORY Price Targets Summary
Oryzon Genomics SA
According to Wall Street analysts, the average 1-year price target for
ORY
is 7.55 EUR
with a low forecast of 4.04 EUR and a high forecast of 12.6 EUR.
Dividends
Current shareholder yield for ORY is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ORY
stock under the Base Case scenario is
1.17
EUR.
Compared to the current market price of 2.71 EUR,
Oryzon Genomics SA
is
Overvalued by 57%.